also capsule changes is prominent in the pathology the term u201c spondylosis u201d is understood as meaning an arthrosis of the vertebral bodies with this arthrosis being characterized by a noninflammatory loss of cartilage from the vertebral bodies and intervertebral disks the pharmaceuticals according to the invention can be administered by inhalative or transdermal administration or by subcutaneous intraarticular intraperitoneal or intravenous injection intraarticular administration or topical application is preferred suitable solid or pharmaceutical preparation forms are for example suspensions emulsions or injectable solutions and preparations having protracted release of active compound in whose preparation customary excipients are used preferably the pharmaceutical preparations are prepared and administered in dose units each unit containing as active constituent a certain dose of the compound of the formula i according to the invention in the case of injection solutions in ampoule form this dose can be up to approximately 300 mg but preferably approximately 10 to 100 mg in the case of injection solutions for intraarticular treatment up to approximately 300 micrograms preferably 100 micrograms for the treatment of an adult patient depending on the activity of the compound according to formula i daily doses of approximately 0 01 mg kg to 10 mg kg of active compound are indicated in the case of systemic administration in the case of the administration of injection solutions daily doses of 0 001 mg kg to 0 005 mg kg of active compound are indicated and.